

[» Coronavirus \(COVID-19\) guidance](#)

The restrictions during our gradual move out of lockdown.

[Home](#) > [Announcements](#) > [All announcements](#) >

Written Statement: Access agreement for the cystic fibrosis medicines Orkambi® and Symkevi®

CABINET STATEMENT

# Written Statement: Access agreement for the cystic fibrosis medicines Orkambi® and Symkevi®

Vaughan Gething, Minister for Health and Social Services

First published: 29 November 2019

Last updated: 29 November 2019

In my written statement of 13 November I confirmed I had approved in principle the terms of an agreement to enable patients in Wales to access the cystic fibrosis medicines (CF) Orkambi® and Symkevi® and to maintain access to Kalydeco® where these medicines are clinically appropriate.

Share this page: [Twitter](#) [Facebook](#) [@](#)

I stated my expectation that, in the interests of Welsh patients, the detailed agreement between NHS Wales and Vertex Pharmaceuticals should be finalised before the end of November. I am very pleased to confirm today this has been achieved.

Clinicians will now be able to begin prescribing these drugs and I expect NHS CF services to determine how best to prioritise patients. We are working with NHS Wales to put arrangements in place to enable access to treatment for the highest priority patients to begin in December. All eligible patients will be offered treatment from 2020.

## First published

29 November 2019

## Last updated

29 November 2019

[Report anything wrong with this page](#)

[Share this page](#)

[Back to top](#)

[Contact us](#) [Accessibility](#) [Copyright statement](#) [Cookies](#) [Privacy](#) [Terms and conditions](#) [Alternative languages](#)